211 related articles for article (PubMed ID: 25310082)
1. Bypassing fluoroquinolone resistance with quinazolinediones: studies of drug-gyrase-DNA complexes having implications for drug design.
Drlica K; Mustaev A; Towle TR; Luan G; Kerns RJ; Berger JM
ACS Chem Biol; 2014 Dec; 9(12):2895-904. PubMed ID: 25310082
[TBL] [Abstract][Full Text] [Related]
2. Fluoroquinolone-gyrase-DNA complexes: two modes of drug binding.
Mustaev A; Malik M; Zhao X; Kurepina N; Luan G; Oppegard LM; Hiasa H; Marks KR; Kerns RJ; Berger JM; Drlica K
J Biol Chem; 2014 May; 289(18):12300-12. PubMed ID: 24497635
[TBL] [Abstract][Full Text] [Related]
3. Overcoming target-mediated quinolone resistance in topoisomerase IV by introducing metal-ion-independent drug-enzyme interactions.
Aldred KJ; Schwanz HA; Li G; McPherson SA; Turnbough CL; Kerns RJ; Osheroff N
ACS Chem Biol; 2013 Dec; 8(12):2660-8. PubMed ID: 24047414
[TBL] [Abstract][Full Text] [Related]
4. Functional Characterization of the DNA Gyrases in Fluoroquinolone-Resistant Mutants of Francisella novicida.
Caspar Y; Siebert C; Sutera V; Villers C; Aubry A; Mayer C; Maurin M; Renesto P
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167561
[TBL] [Abstract][Full Text] [Related]
5. Cleavable-complex formation by wild-type and quinolone-resistant Streptococcus pneumoniae type II topoisomerases mediated by gemifloxacin and other fluoroquinolones.
Yague G; Morris JE; Pan XS; Gould KA; Fisher LM
Antimicrob Agents Chemother; 2002 Feb; 46(2):413-9. PubMed ID: 11796351
[TBL] [Abstract][Full Text] [Related]
6. Quinolone resistance mutations in Streptococcus pneumoniae GyrA and ParC proteins: mechanistic insights into quinolone action from enzymatic analysis, intracellular levels, and phenotypes of wild-type and mutant proteins.
Pan XS; Yague G; Fisher LM
Antimicrob Agents Chemother; 2001 Nov; 45(11):3140-7. PubMed ID: 11600369
[TBL] [Abstract][Full Text] [Related]
7. Impact of mutations in DNA gyrase genes on quinolone resistance in Campylobacter jejuni.
Changkwanyeun R; Yamaguchi T; Kongsoi S; Changkaew K; Yokoyama K; Kim H; Suthienkul O; Usui M; Tamura Y; Nakajima C; Suzuki Y
Drug Test Anal; 2016 Oct; 8(10):1071-1076. PubMed ID: 26857529
[TBL] [Abstract][Full Text] [Related]
8. Probing the differential interactions of quinazolinedione PD 0305970 and quinolones with gyrase and topoisomerase IV.
Pan XS; Gould KA; Fisher LM
Antimicrob Agents Chemother; 2009 Sep; 53(9):3822-31. PubMed ID: 19564360
[TBL] [Abstract][Full Text] [Related]
9. Bacillus anthracis GrlAV96A topoisomerase IV, a quinolone resistance mutation that does not affect the water-metal ion bridge.
Aldred KJ; Breland EJ; McPherson SA; Turnbough CL; Kerns RJ; Osheroff N
Antimicrob Agents Chemother; 2014 Dec; 58(12):7182-7. PubMed ID: 25246407
[TBL] [Abstract][Full Text] [Related]
10. The C7-aminomethylpyrrolidine group rescues the activity of a thio-fluoroquinolone.
Lentz SRC; Chheda PR; Oppegard LM; Towle TR; Kerns RJ; Hiasa H
Biochimie; 2019 May; 160():24-27. PubMed ID: 30763638
[TBL] [Abstract][Full Text] [Related]
11. Molecular determinants of the bacterial resistance to fluoroquinolones: a computational study.
Lupala CS; Gomez-Gutierrez P; Perez JJ
Curr Comput Aided Drug Des; 2013 Jun; 9(2):281-8. PubMed ID: 23106777
[TBL] [Abstract][Full Text] [Related]
12. Suppression of gyrase-mediated resistance by C7 aryl fluoroquinolones.
Malik M; Mustaev A; Schwanz HA; Luan G; Shah N; Oppegard LM; de Souza EC; Hiasa H; Zhao X; Kerns RJ; Drlica K
Nucleic Acids Res; 2016 Apr; 44(7):3304-16. PubMed ID: 26984528
[TBL] [Abstract][Full Text] [Related]
13. Use of gyrase resistance mutants to guide selection of 8-methoxy-quinazoline-2,4-diones.
German N; Malik M; Rosen JD; Drlica K; Kerns RJ
Antimicrob Agents Chemother; 2008 Nov; 52(11):3915-21. PubMed ID: 18765690
[TBL] [Abstract][Full Text] [Related]
14. Contribution of Type II Topoisomerase Mutations to Fluoroquinolone Resistance in Enterococcus faecium from Japanese Clinical Setting.
Urushibara N; Suzaki K; Kawaguchiya M; Aung MS; Shinagawa M; Takahashi S; Kobayashi N
Microb Drug Resist; 2018; 24(1):1-7. PubMed ID: 28504916
[TBL] [Abstract][Full Text] [Related]
15. Hot-spot consensus of fluoroquinolone-mediated DNA cleavage by Gram-negative and Gram-positive type II DNA topoisomerases.
Richter SN; Giaretta G; Comuzzi V; Leo E; Mitchenall LA; Fisher LM; Maxwell A; Palumbo M
Nucleic Acids Res; 2007; 35(18):6075-85. PubMed ID: 17766248
[TBL] [Abstract][Full Text] [Related]
16. Fluoroquinolone-Gyrase-DNA Cleaved Complexes.
Luan G; Drlica K
Methods Mol Biol; 2018; 1703():269-281. PubMed ID: 29177748
[TBL] [Abstract][Full Text] [Related]
17. Mutations in the gyrB, parC, and parE genes of quinolone-resistant isolates and mutants of Edwardsiella tarda.
Kim MS; Jun LJ; Shin SB; Park MA; Jung SH; Kim K; Moon KH; Jeong HD
J Microbiol Biotechnol; 2010 Dec; 20(12):1735-43. PubMed ID: 21193831
[TBL] [Abstract][Full Text] [Related]
18. Drug interactions with Bacillus anthracis topoisomerase IV: biochemical basis for quinolone action and resistance.
Aldred KJ; McPherson SA; Wang P; Kerns RJ; Graves DE; Turnbough CL; Osheroff N
Biochemistry; 2012 Jan; 51(1):370-81. PubMed ID: 22126453
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of binding of fluoroquinolones to the quinolone resistance-determining region of DNA gyrase: towards an understanding of the molecular basis of quinolone resistance.
Madurga S; Sánchez-Céspedes J; Belda I; Vila J; Giralt E
Chembiochem; 2008 Sep; 9(13):2081-6. PubMed ID: 18677735
[TBL] [Abstract][Full Text] [Related]
20. Fluoroquinolone and quinazolinedione activities against wild-type and gyrase mutant strains of Mycobacterium smegmatis.
Malik M; Marks KR; Mustaev A; Zhao X; Chavda K; Kerns RJ; Drlica K
Antimicrob Agents Chemother; 2011 May; 55(5):2335-43. PubMed ID: 21383100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
